Embryonics

Company Overview

Snapshot

Founded in May 2018 by David Silver and Yael Gold-Zamir, Embryonics operates with 1–10 employees. The company was acquired by Rhea Fertility in January 2024, marking a significant milestone in its trajectory.

Business overview

Embryonics is a Health Tech & Life Sciences company focused on improving In-vitro Fertilization (IVF) success rates through AI algorithms. The company develops a suite of AI solutions, including custom hormonal protocols, oocyte and embryo selection (CE marked), and non-invasive genetic screening. By transforming fertility clinic procedures from art to data-based science, Embryonics aims to decrease expenses and elevate success rates for healthcare providers in the global market.

Strategic signal

In January 2024, Embryonics was acquired by Rhea Fertility. This acquisition highlights the increasing consolidation and strategic interest in AI-driven solutions within the fertility sector, signaling a validation of Embryonics' technology and its potential for broader integration into fertility treatment platforms.

Company Intelligence Q&A

When was Embryonics acquired?

Embryonics was acquired by Rhea Fertility in January 2024.

What is Embryonics' core technology?

Embryonics utilizes AI algorithms, including deep learning, computer vision, and machine learning, to enhance In-vitro Fertilization (IVF) success rates.

Which investors participated in Embryonics' funding round?

In January 2021, Embryonics received funding from hiCenter Ventures and Israel Innovation Authority.

What was a notable partnership for Embryonics?

In April 2022, Embryonics partnered with Jaslok Hospital to implement its AI-driven solutions for improving IVF success rates.

What recognition did Embryonics receive in 2019?

In November 2019, Embryonics won a tech prize from European Rabbis for its startup which improves IVF success rates.